CoChat

A Randomised Controlled Trial of Artemether-Lumefantrine Versus Artesunate for Uncomplicated Plasmodium falciparum Treatment in Pregnancy

Open access

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

BACKGROUND: To date no comparative trials have been done, to our knowledge, of fixed-dose artemisinin combination therapies (ACTs) for the treatment of Plasmodium falciparum malaria in pregnancy. Evidence on the safety and efficacy of ACTs in pregnancy is needed as these drugs are being used increasingly throughout the malaria-affected world. The objective of this study was to compare the efficacy, tolerability, and safety of artemether-lumefantrine, the most widely used fixed ACT, with 7 d artesunate monotherapy in the second and third trimesters of pregnancy. METHODS AND FINDINGS: An open-label randomised controlled trial comparing directly observed treatment with artemether-lumefantrine 3 d (AL) or artesunate monotherapy 7 d (AS7) was conducted in Karen women in the border area of northwestern Thailand who had uncomplicated P. falciparum malaria in the second and third trimesters of pregnancy. The primary endpoint was efficacy defined as the P. falciparum PCR-adjusted cure rates assessed at delivery or by day 42 if this occurred later than delivery, as estimated by Kaplan-Meier survival analysis. Infants were assessed at birth and followed until 1 y of life. Blood sampling was performed to characterise the pharmacokinetics of lumefantrine in pregnancy. Both regimens were very well tolerated. The cure rates (95% confidence interval) for the intention to treat (ITT) population were: AS7 89.2% (82.3%-96.1%) and AL 82.0% (74.8%-89.3%), p = 0.054 (ITT); and AS7 89.7% (82.6%-96.8%) and AL 81.2% (73.6%-88.8%), p = 0.031 (per-protocol population). One-third of the PCR-confirmed recrudescent cases occurred after 42 d of follow-up. Birth outcomes and infant (up to age 1 y) outcomes did not differ significantly between the two groups. The pharmacokinetic study indicated that low concentrations of artemether and lumefantrine were the main contributors to the poor efficacy of AL. CONCLUSION: The current standard six-dose artemether-lumefantrine regimen was well tolerated and safe in pregnant Karen women with uncomplicated falciparum malaria, but efficacy was inferior to 7 d artesunate monotherapy and was unsatisfactory for general deployment in this geographic area. Reduced efficacy probably results from low drug concentrations in later pregnancy. A longer or more frequent AL dose regimen may be needed to treat pregnant women effectively and should now be evaluated. Parasitological endpoints in clinical trials of any antimalarial drug treatment in pregnancy should be extended to delivery or day 42 if it comes later. TRIAL REGISTRATION: Current Controlled Trials ISRCTN86353884.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.0050253

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Participant Flow in the Randomised Comparison of AS7 and AL
Figure 1 Participant Flow in the Randomised Comparison of AS7 and ALCC BY · PubMed Central
Figure 2 Schematic Diagram of Routine Antenatal Care and Basic Study Procedures in Pregnancy, at Delivery and Infant Follow-up
Figure 2 Schematic Diagram of Routine Antenatal Care and Basic Study Procedures in Pregnancy, at Delivery and Infant Follow-upCC BY · PubMed Central
Figure 3 Schematic Diagram of Participant Follow-up after Randomization, Embedded Pharmacokinetic Studies, and Follow-up Scenarios D42, day 42; D0, day 0; PCR, polymerase chain reaction, PF, P. falciparum; PV, P. vivax.
Figure 3 Schematic Diagram of Participant Follow-up after Randomization, Embedded Pharmacokinetic Studies, and Follow-up Scenarios D42, day 42; D0, day 0; PCR, polymerase chain reaction, PF, P. falciparum; PV, P. vivax.CC BY · PubMed Central
Figure 4 P. falciparum PCR-Adjusted Cure Rates at Delivery (day 42 if Later) (Left Graph) and at Day 42 of Follow-up (Right Graph) as Estimated by Kaplan-Meier Survival Analysis
Figure 4 P. falciparum PCR-Adjusted Cure Rates at Delivery (day 42 if Later) (Left Graph) and at Day 42 of Follow-up (Right Graph) as Estimated by Kaplan-Meier Survival AnalysisCC BY · PubMed Central
Figure 5 P. falciparum PCR-Adjusted Cure Rates (ITT) Assessed at Delivery (Day 42 if Later) as Estimated by Kaplan-Meier Survival Analysis after Classification of the Enrolment Infection Enrolment infections were classified by PCR genotyping into recrudescent, novel, or primary infections.
Figure 5 P. falciparum PCR-Adjusted Cure Rates (ITT) Assessed at Delivery (Day 42 if Later) as Estimated by Kaplan-Meier Survival Analysis after Classification of the Enrolment Infection Enrolment infections were classified by PCR genotyping into recrudescent, novel, or primary infections.CC BY · PubMed Central
Figure 6 Malaria (P. falciparum or P. vivax) Cure Rates Assessed at Delivery or Day 42 (if Later) as Estimated by Kaplan-Meier Survival Analysis
Figure 6 Malaria (P. falciparum or P. vivax) Cure Rates Assessed at Delivery or Day 42 (if Later) as Estimated by Kaplan-Meier Survival AnalysisCC BY · PubMed Central
Figure 7 The Absolute Change in Haematocrit between Admission and Each Follow-up Day from 7 to 42 Change was calculated for each individual patient and summed as mean and 95% CI for the two treatment groups.
Figure 7 The Absolute Change in Haematocrit between Admission and Each Follow-up Day from 7 to 42 Change was calculated for each individual patient and summed as mean and 95% CI for the two treatment groups.CC BY · PubMed Central
Figure 8 Scatterplot of Lumefantrine Concentration from Capillary Sampling on Day 7 Data are grouped according to the endpoint (recrudescent, novel infection or primary infection) after AL treatment. Geometric mean (ng/ml) displayed within text box.
Figure 8 Scatterplot of Lumefantrine Concentration from Capillary Sampling on Day 7 Data are grouped according to the endpoint (recrudescent, novel infection or primary infection) after AL treatment. Geometric mean (ng/ml) displayed within text box.CC BY · PubMed Central
Figure 9 Scatterplot of Day 7 Lumefantrine Concentrations Versus Enrolment Parasitaemia Units are ng/ml. Data on y-axis are from capillary sampling; x-axis is the enrolment parasitaemia (per μl). Markers identify the primary efficacy endpoint of AL treatment: recrudescent (solid diamonds), novel infections (open diamonds) and no reappearance (×).
Figure 9 Scatterplot of Day 7 Lumefantrine Concentrations Versus Enrolment Parasitaemia Units are ng/ml. Data on y-axis are from capillary sampling; x-axis is the enrolment parasitaemia (per μl). Markers identify the primary efficacy endpoint of AL treatment: recrudescent (solid diamonds), novel infections (open diamonds) and no reappearance (×).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 136

Metadata

Authors
McGready, R., Tan, S. O., Ashley, E. A., Pimanpanarak, M., Viladpai-nguen, J., Phaiphun, L., Wüstefeld, K., Barends, M., Laochan, N., Keereecharoen, L., Lindegardh, N., Singhasivanon, P., White, N. J., & Nosten, F.
Affiliations
  • Mahidol University (TH)
  • Shoklo Malaria Research Unit (TH)
Corresponding author
McGready, Rose
Venue
PLoS Medicine
Published
2008-12-23
Volume
5
Issue
12
Pages
e253
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2008309617
Cited by
136
References
45
Citations by year
2026: 2 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 6 · 2020: 6 · 2019: 5 · 2018: 9 · 2017: 5 · 2016: 7 · 2015: 13 · 2014: 14 · 2013: 9 · 2012: 13
FWCI
12.20
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Greater South Information System
Funders
  • Wellcome Trust
  • Mahidol University
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Phytochemical compounds biological activities
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
Keywords
artemether-lumefantrine, falciparum malaria, malaria in pregnancy, uncomplicated malaria, artemisinin-based combination therapy, cure rate, relapse, pharmacokinetics, lumefantrine, Karen women, birth outcomes, infant outcomes, safety and tolerability, northwestern Thailand
MeSH terms
Artesunate, Artemether, Lumefantrine, Adult, Animals, Antimalarials, Drug Therapy, Combination, Ethanolamines, Female, Fluorenes, Humans, Infant, Infant, Newborn, Plasmodium falciparum, Pregnancy, Thailand, Pregnancy Complications, Parasitic, Malaria, Falciparum, Parasitic Sensitivity Tests, Artemisinins, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomised Controlled Trial of Artemether-Lumefantrine Versus Artesunate for Uncomplicated Plasmodium falciparum Treatment in Pregnancy. https://app.cochat.ai/papers/10.1371/journal.pmed.0050253
The paper
McGready, R., Tan, S. O., Ashley, E. A., Pimanpanarak, M., Viladpai-nguen, J., Phaiphun, L., Wüstefeld, K., Barends, M., Laochan, N., Keereecharoen, L., Lindegardh, N., Singhasivanon, P., White, N. J., & Nosten, F. (2008). A Randomised Controlled Trial of Artemether-Lumefantrine Versus Artesunate for Uncomplicated Plasmodium falciparum Treatment in Pregnancy. PLoS Medicine. https://doi.org/10.1371/journal.pmed.0050253

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.